Humacyte (HUMA) Research & Development (2020 - 2026)

Humacyte (HUMA) has 7 years of Research & Development data on file, last reported at $19.5 million in Q1 2026.

• Research & Development for Q1 2026 came in at $19.5 million, up 26.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.3 million (down 11.37% YoY), and the FY2025 annual result was $69.3 million, down 21.78% from the prior year.
• Research & Development rose to $19.5 million in Q1 2026 per HUMA's latest filing, from $14.6 million in the prior quarter.
• Over five years, Research & Development peaked at $23.8 million in Q2 2024 and troughed at $14.6 million in Q4 2025.
• A 5-year average of $18.7 million and a median of $18.6 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development surged 40.19% in 2023, then dropped 29.29% in 2025.
• A 5-year view of Research & Development shows it stood at $15.0 million in 2022, then surged by 34.92% to $20.2 million in 2023, then increased by 2.36% to $20.7 million in 2024, then retreated by 29.29% to $14.6 million in 2025, then jumped by 33.26% to $19.5 million in 2026.
• Business Quant data shows HUMA's Research & Development at $19.5 million in Q1 2026, $14.6 million in Q4 2025, and $17.3 million in Q3 2025.